Literature DB >> 11502536

Susceptibilities of Mycoplasma hominis, M. pneumoniae, and Ureaplasma urealyticum to GAR-936, dalfopristin, dirithromycin, evernimicin, gatifloxacin, linezolid, moxifloxacin, quinupristin-dalfopristin, and telithromycin compared to their susceptibilities to reference macrolides, tetracyclines, and quinolones.

G E Kenny1, F D Cartwright.   

Abstract

The susceptibilities of Mycoplasma hominis, Mycoplasma pneumoniae, and Ureaplasma urealyticum to eight new antimicrobial agents were determined by agar dilution. M. pneumoniae was susceptible to the new glycylcycline GAR-936 at 0.12 microg/ml and evernimicin at 4 microg/ml, but it was resistant to linezolid. It was most susceptible to dirithromycin, quinupristin-dalfopristin, telithromycin, reference macrolides, and josamycin. M. hominis was susceptible to linezolid, evernimicin, and GAR-936. It was resistant to macrolides and the ketolide telithromycin but susceptible to quinupristin-dalfopristin and josamycin. U. urealyticum was susceptible to evernimicin (8 to 16 microg/ml) and resistant to linezolid. It was less susceptible to GAR-936 (4.0 microg/ml) than to tetracycline (0.5 microg/ml). Telithromycin and quinupristin-dalfopristin were the most active agents against ureaplasmas (0.06 microg/ml). The new quinolone gatifloxacin was active against M. pneumoniae and M. hominis at 0.12 to 0.25 microg/ml and active against ureaplasmas at 1.0 microg/ml. The MICs of macrolides were markedly affected by pH, with an 8- to 32-fold increase in the susceptibility of M. pneumoniae as the pH increased from 6.9 to 7.8. A similar increase in susceptibility with increasing pH was also observed with ureaplasmas. Tetracyclines showed a fourfold increase of activity as the pH decreased 1 U, whereas GAR-936 showed a fourfold decrease in activity with a decrease in pH.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11502536      PMCID: PMC90699          DOI: 10.1128/AAC.45.9.2604-2608.2001

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  29 in total

1.  Resistance of Mycoplasma pneumoniae to macrolides, lincomycin and streptogramin B.

Authors:  T Stopler; D Branski
Journal:  J Antimicrob Chemother       Date:  1986-09       Impact factor: 5.790

2.  In vitro activity of telithromycin (HMR3647), a new ketolide, against clinical isolates of Mycoplasma pneumoniae in Japan.

Authors:  T Yamaguchi; Y Hirakata; K Izumikawa; Y Miyazaki; S Maesaki; K Tomono; Y Yamada; S Kamihira; S Kohno
Journal:  Antimicrob Agents Chemother       Date:  2000-05       Impact factor: 5.191

3.  Comparative activities of telithromycin (HMR 3647), levofloxacin, and other antimicrobial agents against human mycoplasmas.

Authors:  C M Bebear; H Renaudin; A Bryskier; C Bebear
Journal:  Antimicrob Agents Chemother       Date:  2000-07       Impact factor: 5.191

4.  Resistance of Mycoplasma pneumoniae to erythromycin and other antibiotics.

Authors:  Y Niitu; S Hasegawa; T Suetake; H Kubota; S Komatsu; M Horikawa
Journal:  J Pediatr       Date:  1970-03       Impact factor: 4.406

5.  Dissemination of the tetM tetracycline resistance determinant to Ureaplasma urealyticum.

Authors:  M C Roberts; G E Kenny
Journal:  Antimicrob Agents Chemother       Date:  1986-02       Impact factor: 5.191

6.  Susceptibility of Mycoplasma pneumoniae to 21 antibiotics in vitro.

Authors:  R L Jao
Journal:  Am J Med Sci       Date:  1967-06       Impact factor: 2.378

7.  Mutations in the gyrA, parC, and parE genes associated with fluoroquinolone resistance in clinical isolates of Mycoplasma hominis.

Authors:  C M Bebear; J Renaudin; A Charron; H Renaudin; B de Barbeyrac; T Schaeverbeke; C Bebear
Journal:  Antimicrob Agents Chemother       Date:  1999-04       Impact factor: 5.191

8.  Human respiratory tract infections with mycoplasmas and their in vitro susceptibility to tetracyclines and some other antibiotics.

Authors:  P A Mårdh
Journal:  Chemotherapy       Date:  1975       Impact factor: 2.544

9.  Enhancing effect on alkalinization of the medium on the activity of erythromycin against gram-negative bacteria.

Authors:  L D Sabath; V Lorian; D Gerstein; P B Loder; M Finland
Journal:  Appl Microbiol       Date:  1968-09

10.  Tetracycline-resistant Mycoplasma hominis strains contain streptococcal tetM sequences.

Authors:  M C Roberts; L A Koutsky; K K Holmes; D J LeBlanc; G E Kenny
Journal:  Antimicrob Agents Chemother       Date:  1985-07       Impact factor: 5.191

View more
  44 in total

1.  Activities of the glycylcycline tigecycline (GAR-936) against 1,924 recent European clinical bacterial isolates.

Authors:  D Milatovic; F-J Schmitz; J Verhoef; A C Fluit
Journal:  Antimicrob Agents Chemother       Date:  2003-01       Impact factor: 5.191

2.  Population pharmacokinetics of tigecycline in patients with complicated intra-abdominal or skin and skin structure infections.

Authors:  S A Van Wart; J S Owen; E A Ludwig; A K Meagher; J M Korth-Bradley; B B Cirincione
Journal:  Antimicrob Agents Chemother       Date:  2006-08-28       Impact factor: 5.191

3.  Activity of Garenoxacin against Macrolide-Susceptible and -Resistant Mycoplasma pneumoniae.

Authors:  Tsutomu Yamazaki; Tsuguo Sasaki; Masahiro Takahata
Journal:  Antimicrob Agents Chemother       Date:  2007-03-26       Impact factor: 5.191

4.  Clonal diversity and resistance mechanisms in tetracycline-nonsusceptible Streptococcus pneumoniae isolates in Poland.

Authors:  Radosław Izdebski; Ewa Sadowy; Janusz Fiett; Paweł Grzesiowski; Marek Gniadkowski; Waleria Hryniewicz
Journal:  Antimicrob Agents Chemother       Date:  2007-01-08       Impact factor: 5.191

Review 5.  Mycoplasma pneumoniae and its role as a human pathogen.

Authors:  Ken B Waites; Deborah F Talkington
Journal:  Clin Microbiol Rev       Date:  2004-10       Impact factor: 26.132

6.  Autoinfection as a cause of postpartum subdural empyema due to Mycoplasma hominis.

Authors:  N J Hos; C Bauer; T Liebig; G Plum; H Seifert; J Hampl
Journal:  Infection       Date:  2014-12-10       Impact factor: 3.553

7.  Comparative in vitro activities of the investigational fluoroquinolone DC-159a and other antimicrobial agents against human mycoplasmas and ureaplasmas.

Authors:  Ken B Waites; Donna M Crabb; Lynn B Duffy
Journal:  Antimicrob Agents Chemother       Date:  2008-07-28       Impact factor: 5.191

Review 8.  Telithromycin.

Authors:  Keri Wellington; Stuart Noble
Journal:  Drugs       Date:  2004       Impact factor: 9.546

Review 9.  Newer antibacterial drugs for a new century.

Authors:  Gina Devasahayam; William M Scheld; Paul S Hoffman
Journal:  Expert Opin Investig Drugs       Date:  2010-02       Impact factor: 6.206

10.  In vitro activities of the newer quinolones garenoxacin, gatifloxacin, and gemifloxacin against human mycoplasmas.

Authors:  S Pereyre; H Renaudin; C Bébéar; C M Bébéar
Journal:  Antimicrob Agents Chemother       Date:  2004-08       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.